ImmunityBio, Inc.: all 115 studies
Page 2 of 2. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.
- Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid TumorsCompletedNCT02235688Phase 1
- A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder CancerActive, not recruitingNCT02138734Phase 1/2
- Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid TumorsCompletedNCT01706835Phase 1
- Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid TumorsCompletedNCT01673438Phase 1
- ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid LeukemiaWithdrawnNCT01478074Phase 1
- Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid TumorsCompletedNCT01337505Phase 1
- A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid TumorsCompletedNCT01325558Phase 1
- QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCompletedNCT00974896Phase 1
- QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT00900809Phase 1
- Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress SyndromeCompletedNCT00879606Phase 2
- QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal CarcinomaCompletedNCT00813605Phase 2
- A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras MutationCompletedNCT00655161Phase 2
- QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell TumorsCompletedNCT00563680Phase 2
- Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas CancerCompletedNCT00300950Phase 2
- Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C InfectionCompletedNCT00124215Phase 1